WHA 70: Statement of Knowledge Ecology International – Global vaccine action plan
On Monday, 29 May 2017, Knowledge Ecology International delivered the following intervention on the Global vaccine action plan. The statement was delivered by James Love.
WHA70: Statement of Knowledge Ecology International on antimicrobial resistance
On Wednesday, 24 May 2017, Knowledge Ecology International delivered the following intervention on antimicrobial resistance. This statement was read by Andrew Goldman.
KEI would like to call attention to a proposal introduced in the United States Congress, as Senate Bill 771, sponsored by 16 US Senators, and HR 1776, which has 14 sponsors in the House of Representatives.SEC. 409K of the bill is titled, “PRIZE FUND FOR NEW AND MORE EFFECTIVE TREATMENTS OF BACTERIAL INFECTIONS.”
SCCR 32: IFLA on Orphan Works
>> IFLA: Thank you again Mr. Chair for allowing IFLA to take the floor. IFLA supports initiatives to support and make available cumulative knowledge and cultural heritage and recognize the role of libraries and archives in that respect. We further… Continue Reading
KEI Comments for 70th World Health Assembly Listening Session at DHHS
Today KEI attended the annual listening session at DHHS, when speakers are alotted no more than 1.5 minutes to speak on a specific agenda item, with no more than two agenda items per speaker. Our brief comments were focused on advancing the delinkage approach in the contexts of the GSPOA, CEWG, and cancer.
Experts, NGOs ask WHA delegates to support feasibility study of funding cancer research without high prices
On May 3, 2017, 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asked delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. The groups and experts sent a letter to the delegates.
U.S. Army Rejects Pricing Concerns in Grant of Exclusive Patent License to Sanofi on Zika Vaccine
Today, KEI received a letter from the U.S. Army dated April 21, 2017, signed by Barry M. Datlof, in which the Army largely rejected concerns raised in comments submitted by KEI and various other public interest groups related to the proposed grant of an exclusive license to the French drug company Sanofi on a U.S. Army-invented vaccine for Zika virus.
Continue ReadingKEI 10 March 2017 Comments on Army Exclusive License on Zika Virus Vaccine Patents to Sanofi
On March 10, 2017, KEI filed our 3rd set of comments with the U.S. Army Medical Research and Material Command (USAMRMC) on their proposed grant of an exclusive license on Zika virus vaccine patents to the French pharmaceutical company Sanofi.
KEI initial opposition to U.S. Army grant of exclusive license to Sanofi on patents for Zika virus vaccine
December 21, 2016 — KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.
2016 KEI application to WHO to put enzalutamide on the Essential Medicines List (EML)
KEI’s 2016 Application for T-DM1 on the WHO EML